PDLI · PDL BioPharma, Inc

-

Please sign in to comment on PDLI

1 Comment

Admin

3 years, 7 months ago

PDL BioPharma, Inc is currently in a long term downtrend where the price is trading 15.5% below its 200 day moving average.

From a valuation standpoint, the stock is 99.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 5.6.

PDL BioPharma, Inc's total revenue sank by 88.2% to $5M since the same quarter in the previous year.

Its net income has dropped by 181.0% to $-50M since the same quarter in the previous year.

Finally, its free cash flow grew by 1278.2% to $64M since the same quarter in the previous year.

Based on the above factors, PDL BioPharma, Inc gets an overall score of 2/5.

CurrencyCode	USD
Exchange	NASDAQ
ISIN	US69329Y1047
Sector	Healthcare
Industry	Biotechnology

Beta	1.14
Target Price	2.5
PE Ratio	476.67
Dividend Yield	0.0%
Market Cap	282M

ABOUT

PDL BioPharma, Inc

PDL BioPharma, Inc. manages various patents in the United States and internationally. The company's patents cover humanization of antibodies. It also offers notes and other long-term receivables services, as well as engages in the equity investment activities. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.

PDLI · PDL BioPharma, Inc

-

PDL BioPharma, Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest PDL BioPharma, Inc using a moving average strategy